| Ticker | Company | ~May 2025 | ~May 2026 | 1Y Return | Market Cap | Consensus | HF Score |
|---|---|---|---|---|---|---|---|
| ARGX ★ | argenx SE | ~$530 | ~$530 | +45.8% | $52B | Strong Buy | 0.08 |
| REGN | Regeneron Pharma | ~$680 | ~$730 | ~+7% | $77B | Buy | 0.55 |
| ALNY | Alnylam Pharmaceuticals | ~$230 | ~$250 | ~+9% | $33B | Strong Buy | 0.40 |
| INCY | Incyte | ~$72 | ~$70 | ~-3% | $14B | Hold | 0.28 |
| GMAB | Genmab | ~$30 | ~$28 | ~-7% | $18B | Buy | 0.20 |
★ ARGX +45.8% 1-year return significantly outperformed peers. Note: current price vs. 1-year ago price comparison on 12M basis reflects the strong Vyvgart commercial ramp and 2025 profitability inflection. TipRanks 1Y return figure may reflect different base periods.
| Firm | Rating | PT |
|---|---|---|
| Goldman Sachs | Buy | $850 |
| Morgan Stanley | Strong Buy | $1,100 |
| JP Morgan | Strong Buy | $1,200 |
| Jefferies | Strong Buy | $1,150 |
| Leerink Partners | Strong Buy | $1,250 |
| RBC Capital | Buy | $900 |
| Citi | Buy | $950 |
| UBS | Hold | $520 |
| Wells Fargo | Buy | $1,000 |
| BofA | Buy | $1,050 |
| Fiscal Year | Revenue (€) | YoY Growth | Net Income/Loss (€) | Net Margin | Free Cash Flow (€) | Stage |
|---|---|---|---|---|---|---|
| FY2016 | €44M | — | -€34M | -77% | -€44M | Clinical |
| FY2017 | €75M | +70% | -€79M | -105% | -€78M | Clinical |
| FY2018 | €66M | -12% | -€217M | -329% | -€195M | Clinical (Phase 3 ramp) |
| FY2019 | €68M | +3% | -€356M | -524% | -€380M | Clinical (multiple trials) |
| FY2020 | €123M | +81% | -€527M | -428% | -€500M | Clinical (Vyvgart Phase 3) |
| FY2021 | €165M | +34% | -€647M | -392% | -€650M | Late clinical; Vyvgart approved Dec'21 |
| FY2022 | €736M | +346% | -€567M | -77% | -€450M | Commercial launch year 1 |
| FY2023 | €1.82B | +147% | -€196M | -10.8% | -€110M | Commercial ramp; 5 indications |
| FY2024 | €3.08B | +69% | €460M | 14.9% | €350M | Profitability inflection |
| FY2025 | €4.15B | +34.7% | €1.29B | 31.1% | €844M | Scaled profitable biopharma |
ARGX went from a clinical-stage company burning €650M/year in cash (FY2021) to a profitable biopharma generating €844M in FCF (FY2025) — in just 4 years. Revenue exploded from €165M (FY2021) to €4.15B (FY2025), a 25× increase. Net margin went from -392% (deep losses) to a record +31.1%. This is the commercial launch trajectory of Vyvgart (efgartigimod alfa) — which has now become the standard of care for generalized myasthenia gravis globally and is expanding into multiple other FcRn-mediated diseases. The company is unambiguously getting dramatically more profitable on both top and bottom line, with further upside as additional indications (CIDP, thyroid eye disease, PV) scale up.
| Indication | Approval Status | FY2025 Est. Revenue | Market Size | Notes |
|---|---|---|---|---|
| gMG (IV) | ✅ FDA approved Dec'21 | ~€1.8B | ~$3B peak | First-line standard of care; market leading share |
| gMG (SC, Vyvgart Hytrulo) | ✅ FDA approved Jun'23 | ~€800M | Overlaps with IV | Subcutaneous formulation driving switch |
| CIDP (chronic inflamm. demyel. polyneuropathy) | ✅ FDA approved Jun'24 | ~€600M | ~$5B peak | Rapidly becoming standard of care; CIDP market 3× larger than gMG |
| ITP (immune thrombocytopenia) | ✅ FDA approved (SC) | ~€250M | ~$2B peak | Competitive but growing |
| TED (thyroid eye disease) | 🔄 Phase 3; FDA filing expected | Early | ~$2B peak | Competing with tepezza; positive Phase 3 data 2025 |
| Pemphigus Vulgaris (PV) | 🔄 Phase 2/3 | Pipeline | ~$1.5B peak | Rare autoimmune; strong early efficacy signals |
All 12 MAs aligned bullish. RSI 60.1 suggests momentum without being overbought. Oscillator sell signals are typical for a trending stock at this RSI level.
| Category | Assessment | Score | Notes |
|---|---|---|---|
| Business Quality | Excellent | 9/10 | World-class FcRn platform; 6 approved indications; expanding pipeline |
| Revenue Growth | Exceptional | 10/10 | €165M → €4.15B in 4 years (25×); CIDP adding another major leg |
| Profitability Trend | Excellent | 9/10 | Losses → 31.1% net margin in 4 years; FCF €844M; inflection story complete |
| Valuation | Elevated | 6/10 | 45.4× P/E; priced for significant continued growth |
| Analyst Sentiment | Strong Buy | 9/10 | 16B/1H/0S; avg PT $1,045 (+97% upside) — exceptional conviction |
| Hedge Fund Activity | Low | 4/10 | HF Score 0.08 — low institutional 13F activity (may reflect foreign-listed structure) |
| Technical Setup | Buy | 7/10 | All 12 MAs bullish; RSI 60.1; oscillators cautionary |
| Key Risk | Competition | — | FcRn class competition from J&J/UCB; CIDP adoption pace |
| OVERALL RATING | STRONG BUY | 8.0/10 | Remarkable clinical-to-commercial transformation; platform story with 30B+ combined TAM; CIDP is key catalyst to watch |